Alector Inc. Chief Operating Officer Shehnaaz Suliman said her company’s deal with Glaxosmithkline plc (GSK) – worth as much as $2.2 billion – “allows us to expand into indications that we have been quite thoughtful about doing, but in a more expeditious manner. This is really an opportune time to continue to explore the biology of these programs across multiple indications.”
Merck KGaA is partnering with Neuroloop GmbH, a subsidiary of B. Braun SE, to develop a neurostimulator device that can complement existing drug therapies for people with chronic inflammatory diseases. The collaboration aims to adapt Neuroloop’s neurostimulation platform to enable targeted treatment of chronic inflammatory ailments. The new bioelectronics program intends to open up new technologies and markets that are close to Merck’s electronics and health care business sectors.
In a deal that could be worth up to $565 million, Simcere Pharmaceutical Group Ltd. licensed in glutaminyl cyclase inhibitor varoglutamstat (PQ-912) and monoclonal N3pE-antibody PBD-C06, which target the neurotoxic amyloid species N3pE (pGlu-Abeta), from Vivoryon Therapeutics AG to develop and commercialize for Alzheimer’s disease in greater China.
PARIS – Aptargroup Inc. is negotiating to buy Voluntis SA in a move that would complement its existing digital solutions portfolio and expand services to address multiple conditions and chronic diseases. "By being part of Aptar, we will be able to pursue a common ambition aimed at providing a complete digital health platform combining connected devices and digital therapeutics," Pierre Leurent, CEO and co-founder of Voluntis, told BioWorld.
While the number of biopharma’s nonprofit deals and grants, as well as their values, have dropped by more than 20% compared with last year, almost 71% of the combined funds are targeting COVID-19 therapeutics, vaccines and other pandemic efforts.
Boehringer Ingelheim GmbH has begun a three-year collaboration with researchers at Australia’s WEHI, looking into a potentially powerful approach to targeted protein degradation also being studied by its German rival Merck KGaA.
Boston Scientific Corp. has exercised an option as part of a 2020 agreement to acquire Farapulse Inc. in full, folding the startup’s pulsed electric field ablation technology for the treatment of atrial fibrillation and other cardiac arrhythmias into its own electrophysiology portfolio. With a 27% stake in Farapulse already, it will pay about $295 million for the remainder.
Glaxosmithkline plc CEO Emma Walmsley has set out further details of the company’s forthcoming split, saying that the firm’s late-stage pipeline could help deliver sales of more than £33 billion by 2031.
Zai Lab Ltd. and Macrogenics Inc. have announced a collaboration and license agreement involving up to four immuno-oncology molecules in a deal potentially worth upward of $1.5 billion. The deal makes sense as both are upcoming companies at around the same stage in development – making progress in oncology with first products recently approved by regulators.